Use of GLP-1 receptor agonists in Prader-Willi syndrome: report of six cases
After having her IUD removed in May 2024, Hatcher had a period that lasted 45 days, and started experiencing symptoms of PCOS, such as fatigue and irregular menstrual cycles
Retatrutides safety profile is consistent with whats already been observed GLP-1 receptor agonists and combined GLP-1/GIP receptor agonists, meaning the expected side effects are primarily gastrointestinal (GI) in nature: Nausea, vomiting, diarrhea, and constipation
Your plateau is not actually a plateau Weight loss stalls are not always compound-related
A 0.5 mL syringe has 50 units total, while a 1 mL syringe has 100 units
It has Phase 3 REDEFINE-1 data showing about 22.7% weight loss at 68 weeks, and an NDA was filed with FDA in December 2025